Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634029 | 0.92 | BACE1 (0.50) | BACE1CTSDBACE2 | |
| SCHEMBL13634028 | 0.78 | TFPI (0.53) | BACE1BACE2PTPN1 | |
| SCHEMBL14344621 | 0.75 | BACE1 (0.39) | BACE1CTSDBACE2NPY1RNPY2R | |
| SCHEMBL30350026 | 0.73 | KISS1R (0.56) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL30512662 | 0.72 | NPY4R (0.62) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL13781455 | 0.70 | TFPI (0.53) | BACE1BACE2PTPN1 | |
| SCHEMBL29520890 | 0.70 | BACE1 (0.57) | BACE1CTSDBACE2NPY1RNPY2R | |
| SCHEMBL13634040 | 0.69 | TFPI (0.56) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL30633119 | 0.69 | BACE1 (0.61) | BACE1CTSDBACE2NPY1RNPY2R | |
| SCHEMBL29641709 | 0.69 | FOLH1 (0.52) | NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191123-A1 | NOVEL IMAGING AGENTS | MMP1, CD68, KIT | BACE1 4028/4885CTSD 753/4885BACE2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.